Tarsus Pharmaceuticals, Inc.
TARS
$40.81
$1.995.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 183.68% | 407.86% | 2,471.78% | -- | 1,004.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 183.68% | 407.86% | 2,471.78% | -- | 1,004.56% |
| Cost of Revenue | 43.00% | 50.12% | 23.14% | 22.13% | -- |
| Gross Profit | 322.59% | 3,187.13% | 408.62% | 303.17% | 455.76% |
| SG&A Expenses | 64.79% | 60.52% | 90.97% | 189.97% | 241.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.21% | 57.89% | 71.19% | 125.82% | 137.86% |
| Operating Income | 30.26% | 45.06% | 38.53% | -1.47% | -51.03% |
| Income Before Tax | 29.70% | 44.84% | 40.18% | -5.94% | -52.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.70% | 44.84% | 40.18% | -5.94% | -52.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.70% | 44.84% | 40.18% | -5.94% | -52.57% |
| EBIT | 30.26% | 45.06% | 38.53% | -1.47% | -51.03% |
| EBITDA | 30.99% | 45.61% | 38.86% | -1.30% | -50.57% |
| EPS Basic | 36.93% | 54.30% | 52.27% | 24.89% | -15.59% |
| Normalized Basic EPS | 34.16% | 57.19% | 52.09% | 29.36% | -16.94% |
| EPS Diluted | 36.77% | 54.30% | 52.27% | 24.89% | -15.02% |
| Normalized Diluted EPS | 34.16% | 57.19% | 52.09% | 29.36% | -16.94% |
| Average Basic Shares Outstanding | 11.46% | 20.71% | 25.34% | 41.05% | 32.00% |
| Average Diluted Shares Outstanding | 11.46% | 20.71% | 25.34% | 41.05% | 32.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |